Scientific article

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

Published inOncotarget, vol. 7, no. 45, p. 73337-73346
Publication date2016

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-positive invasive lobular breast carcinomas (ILC). All the 529 ILC surgically-excised registered at Institut Curie in the years 2005 to 2008 were reviewed. Thirty-nine grade 3 ERBB2-negative ILC and 16 ERBB2-positive ILC were retrieved and subjected to Sanger sequencing of the ERBB2 and ERBB3 activation mutation hotspots (ERBB2: exons 8, 17, 19, 20, 21; ERBB3: exons 3, 6, 7, 8). Among the 39 grade 3 ERBB2-negative ILC, six tumors were found to have at least one detectable ERBB2 activating mutation (incidence rate: 15%, 95%CI [4%-27%]). No ERBB2 mutation was found among the 16 ERBB2-positive ILC. No ERBB3 mutation was found in any of the 55 ILC. ERBB2 mutations were statistically associated with solid ILC features (p=0.01). Survival analyses showed no significant prognostic impact of ERBB2 mutations. Our study demonstrates that high grade ERBB2-negative ILC display a high frequency of ERBB2 mutations, and should be subjected to systematic genetic screening.

Citation (ISO format)
DENIZIAUT, Gabrielle et al. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. In: Oncotarget, 2016, vol. 7, n° 45, p. 73337–73346. doi: 10.18632/oncotarget.11819
Main files (1)
Article (Published version)
ISSN of the journal1949-2553

Technical informations

Creation11/24/2016 11:39:00 AM
First validation11/24/2016 11:39:00 AM
Update time03/15/2023 1:02:06 AM
Status update03/15/2023 1:02:05 AM
Last indexation01/16/2024 10:29:08 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack